[Federal Register Volume 62, Number 167 (Thursday, August 28, 1997)]
[Notices]
[Page 45667]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-22935]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 97N-0221]


Benzodiazepines and Related Substances; Criteria for Scheduling 
Recommendations Under the Controlled Substance Act; Notice of Public 
Hearing Modification

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) in conjunction with 
other Federal agencies is announcing that the part 15 public hearing on 
benzodiazepines and related substances originally scheduled for 
September 11 and 12, 1997, will be held only on September 11, 1997. The 
public hearing will not continue to September 12, 1997. The decision to 
forego the second day is based on the limited number of respondents 
submitting notices of participation in the hearing.

DATES: The hearing will be held on Thursday September 11, 1997, from 9 
a.m. to 4 p.m. The closing date for comments will be October 17, 1997.

ADDRESSES: The public hearing will be held at the Renaissance Hotel, 
999 Ninth St. NW., Washington, DC. Comments are to be sent to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, 
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Transcripts of the 
public hearing may be requested in writing from the Freedom of 
Information Office (HFI-35), Food and Drug Administration, 5600 Fishers 
Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days 
after the hearing, at a cost of 10 cents per page. The transcript of 
the public hearing, copies of data and information submitted during the 
hearing, and any written comments will be available for review at the 
Dockets Management Branch (address above) between 9 a.m. and 4 p.m., 
Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Nicholas P. Reuter, Office of Health 
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, rm. 
15-22, Rockville, MD 20857, 301-827-1696, FAX 301-443- 0232, e-mail 
``[email protected]''.

SUPPLEMENTARY INFORMATION:
    In a notice published in the Federal Register of June 19, 1997 (62 
FR 33418), FDA in conjunction with other Federal agencies announced 
that it would convene a part 15 public hearing on benzodiazepines and 
related substances. The public hearing was scheduled for Thursday, 
September 11, 1997 and part of Friday, September 12, 1997.
    Persons who wished to participate in the hearing were asked to file 
a notice of participation with the Dockets Management Branch (address 
above) on or before August 14, 1997. In response to that notice, eight 
individuals representing various organizations indicated their interest 
in participating in the hearing. FDA, along with the other 
participating agencies, have determined that the number of individuals 
indicating an interest in participating in the hearing can be 
accommodated in one full day and that there is no need to continue the 
hearing to the second day. Therefore, the public hearing will be held 
at the address above from approximately 9 a.m. until 4 p.m. on 
September 11, 1997.
    Interested parties may still sign up to participate in the hearing. 
The June 19, 1997, notice included a provision whereby persons may give 
oral notice of participation by calling Nicholas Reuter (telephone 
number above) no later than August 29, 1997. This notice extends until 
September 3, 1997, the opportunity to give oral notice of 
participation. Those persons who give oral notice of participation 
should also submit written notice containing the information described 
above to the Dockets Management Branch by the close of business 
September 8, 1997.

    Dated: August 22, 1997.
William B. Schultz,
Deputy Commissioner for Policy.
[FR Doc. 97-22935 Filed 8-25-97; 11:56 am]
BILLING CODE 4160-01-F